These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 30346267)
1. Systematic Screening Using Luminex for De Novo C3d Fixing of Class II Donor-Specific Antibodies Is Correlated With Luminex Mean Fluorescence Intensity in Renal Transplant Patients. Villemaire M; Jouve T; Bourdin A; Janbon B; Pinel N; Tetaz R; Terrier N; Rostaing L; Masson D; Malvezzi P Exp Clin Transplant; 2019 Aug; 17(4):483-489. PubMed ID: 30346267 [TBL] [Abstract][Full Text] [Related]
2. Luminex Solid-Phase Crossmatch for De Novo Donor-Specific Antibodies in Living-Donor Related Transplants. Mehrotra S; Sharma RK; Mayya M; Gupta A; Prasad N; Kaul A; Bhadauria DS Exp Clin Transplant; 2017 Aug; 15(4):394-399. PubMed ID: 28447925 [TBL] [Abstract][Full Text] [Related]
3. Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort. Gautier Vargas G; Olagne J; Parissiadis A; Joly M; Cognard N; Perrin P; Froelich N; Guntz P; Gachet C; Moulin B; Caillard S Transplantation; 2020 Oct; 104(10):2148-2157. PubMed ID: 31895344 [TBL] [Abstract][Full Text] [Related]
4. Intensity of de novo DSA detected by Immucor Lifecodes assay and C3d fixing antibodies are not predictive of subclinical ABMR after Kidney Transplantation. Bertrand D; Kaveri R; Laurent C; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Thierry A; François A; Hau F; Etienne I; Guerrot D; Farce F PLoS One; 2021; 16(4):e0249934. PubMed ID: 33886604 [TBL] [Abstract][Full Text] [Related]
5. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients. Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941 [TBL] [Abstract][Full Text] [Related]
6. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients. Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780 [TBL] [Abstract][Full Text] [Related]
7. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure. Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma AJ; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG J Am Soc Nephrol; 2018 Sep; 29(9):2279-2285. PubMed ID: 30049681 [No Abstract] [Full Text] [Related]
9. Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies. Kim JJ; Shaw O; Martin C; Michaelides G; Balasubramaniam R; Sebire NJ; Mamode N; Dorling A; Vaughan R; Marks SD Pediatr Nephrol; 2018 Jan; 33(1):167-174. PubMed ID: 28918487 [TBL] [Abstract][Full Text] [Related]
10. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies. Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study. Eskandary F; Bond G; Kozakowski N; Regele H; Marinova L; Wahrmann M; Kikić Ž; Haslacher H; Rasoul-Rockenschaub S; Kaltenecker CC; König F; Hidalgo LG; Oberbauer R; Halloran PF; Böhmig GA Transplantation; 2017 Mar; 101(3):631-641. PubMed ID: 27120452 [TBL] [Abstract][Full Text] [Related]
12. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience. Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J Clin Transpl; 2014; ():223-30. PubMed ID: 26281149 [TBL] [Abstract][Full Text] [Related]
13. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. Süsal C; Wettstein D; Döhler B; Morath C; Ruhenstroth A; Scherer S; Tran TH; Gombos P; Schemmer P; Wagner E; Fehr T; Živčić-Ćosić S; Balen S; Weimer R; Slavcev A; Bösmüller C; Norman DJ; Zeier M; Opelz G; Transplantation; 2015 Sep; 99(9):1976-80. PubMed ID: 25769065 [TBL] [Abstract][Full Text] [Related]
14. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Lee PC; Ozawa M Clin Transpl; 2007; ():219-26. PubMed ID: 18642453 [TBL] [Abstract][Full Text] [Related]
15. Value of C3d assay and IgG subclass in the prediction of the flow cytometry cross-match result for renal transplantation. Contreras AG; Casillas-Abundis A; Alberú J; Llorente L; Lima G; Arvizu A; de Santiago A; Vilatobá M; Granados J; Morales-Buenrostro LE; Cruz R; Arreola-Guerra JM Transpl Immunol; 2018 Oct; 50():8-14. PubMed ID: 29885443 [TBL] [Abstract][Full Text] [Related]
16. C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study. Lee DR; Kim BC; Kim JP; Kim IG; Jeon MY Transplant Proc; 2018 Dec; 50(10):3452-3459. PubMed ID: 30503524 [TBL] [Abstract][Full Text] [Related]
17. Analysis of Panel Reactive Antibodies in Renal Transplant Recipients Detected by Luminex: A Single-Center Experience. İnal A; Özçelik Ü; Ogan Uyanık E; Külah E; Demirağ A Exp Clin Transplant; 2016 Aug; 14(4):401-4. PubMed ID: 26517205 [TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Rose ML; Smith JD Hum Immunol; 2009 Aug; 70(8):605-9. PubMed ID: 19375471 [TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767 [TBL] [Abstract][Full Text] [Related]
20. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen. Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]